Maria Agustina Fuentes

US Patent:

7807158, Oct 5, 2010

Filed:

Jan 3, 2006

Appl. No.:

11/325197

Inventors:

Josef Endl - Weilheim, DE
Maria Elena Fuentes - Sunnyvale CA, US
Yvo Graus - Odijk, NL
Adelbert Grossmann - Eglfing, DE
Sebastian Neumann - Weilheim, DE
Paul Parren - Odijk, NL
Frank Rebers - Utrecht, NL
Joerg Thomas Regula - Munich, DE
Ralf Schumacher - Penzberg, DE
Stefan Seeber - Penzberg, DE
Jan Olaf Stracke - Penzberg, DE
Kay-Gunnar Stubenrauch - Penzberg, DE
Jan Van De Winkel - Zeist, NL
Martine Van Vugt - Houten, NL
Sandra Vereecken-Verploegen - Nieuwegein, NL

Assignee:

Roche Palo Alto LLC - Palo Alto CA

International Classification:

A61K 39/395

US Classification:

4241331, 4241431, 5303873

Abstract:

The instant specification discloses an antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.

US Patent:

7868141, Jan 11, 2011

Filed:

Dec 5, 2008

Appl. No.:

12/315863

Inventors:

Joseph Endl - Wilhelm, DE
Elsie M. Eugui - Belmont CA, US
Maria Elena Fuentes - Sunnyvale CA, US
Yvo Graus - Odijk, NL
Aran Frank Labrijn - Amsterdam, NL
Martin Lanzendoerfer - Tutzing, DE
Paul Parren - Odijk, NL
Frank Rebers - Utrecht, NL
Ralf Schumacher - Penzberg, DE
Stefan Seeber - Penzberg, DE
Jan Van De Winkel - Zeist, NL
Martine Van Vugt - Houten, NL

Assignee:

Roche Palo Alto LLC - Palo Alto CA

International Classification:

C07K 16/00
A61K 39/395

US Classification:

5303871, 4241301

Abstract:

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

US Patent:

20110070239, Mar 24, 2011

Filed:

Dec 1, 2010

Appl. No.:

12/958278

Inventors:

Joseph Endl - Wilhelm, DE
Elsie M. Eugui - Belmont CA, US
Maria Elena Fuentes - Sunnyvale CA, US
Yvo Graus - Odijk, NL
Aran Frank Labrijn - Amsterdam, NL
Martin Lanzendoerfer - Tutzing, DE
Paul Parren - Odijk, NL
Frank Rebers - Utrecht, NL
Ralf Schumacher - Penzberg, DE
Stefan Seeber - Penzberg, DE
Jan Van De Winkel - Zeist, NL
Martine Van Vugt - Houten, NL

International Classification:

A61K 39/395
C07H 21/04
C12P 21/06
C12N 5/074

US Classification:

4241441, 5303881, 435 691, 4353201, 435325, 536 232

Abstract:

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor Cq. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

US Patent:

20110086026, Apr 14, 2011

Filed:

Jul 26, 2010

Appl. No.:

12/843225

Inventors:

Josef Endl - Weilheim, DE
Maria Elena Fuentes - Sunnyvale CA, US
Yvo Graus - Odijk, NL
Adelbert Grossmann - Eglfing, DE
Sebastian Neumann - Weilheim, DE
Paul Parren - Odijk, NL
Frank Rebers - Utrecht, NL
Joerg Thomas Regula - Muenchen, DE
Ralf Schumacher - Penzberg, DE
Stefan Seeber - Penzberg, DE
Jan Olaf Stracke - Penzberg, DE
Kay-Gunnar Stubenrauch - Penzberg, DE
Jan Van De Winkel - Zeist, NL
Martine Van Vugt - Houten, NL
Sandra Vereecken-Verploegen - Nieuwegein, NL

International Classification:

A61K 39/395
C07H 21/00
C07K 16/00
A61P 11/06
A61P 37/02
C12N 5/10
C12P 21/02
C12N 15/63
C12N 1/00

US Classification:

4241331, 536 2353, 5303891, 435334, 435 696, 4353201, 435243

Abstract:

An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.

US Patent:

7501496, Mar 10, 2009

Filed:

Sep 16, 2005

Appl. No.:

11/229162

Inventors:

Joseph Endl - Wilhelm, DE
Elsie M. Eugui - Belmont CA, US
Maria Elena Fuentes - Sunnyvale CA, US
Yvo Graus - Odijk, NL
Aran Frank Labrijn - Amsterdam, NL
Martin Lanzendoerfer - Tutzing, DE
Paul Parren - Odijk, NL
Frank Rebers - Utrecht, NL
Ralf Schumacher - Penzberg, DE
Stefan Seeber - Penzberg, DE
Jan Van De Winkel - Zeist, NL
Martine Van Vugt - Houten, NL

Assignee:

Roche Palo Alto LLC - Palo Alto CA

International Classification:

C07K 16/00
C07K 16/28
A61K 39/395

US Classification:

5303873, 5303881, 53038822, 5303887, 4241331, 4241411, 4241521, 4241531

Abstract:

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

US Patent:

20220347173, Nov 3, 2022

Filed:

Jun 27, 2019

Appl. No.:

17/255168

Inventors:

- South San Francisco CA, US
Prabha Ibrahim - Mountain View CA, US
Maria Fuentes - San Francisco CA, US

International Classification:

A61K 31/498
A61K 31/421
A61K 31/433
A61K 31/4439
A61K 31/166
A61K 31/415
A61P 1/16
A61K 45/06

Abstract:

Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.

US Patent:

20220257570, Aug 18, 2022

Filed:

Jul 28, 2020

Appl. No.:

17/629988

Inventors:

- South San Francisco CA, US
Maria Fuentes - San Francisco CA, US
P. T. Ravi Rajagopalan - San Ramon CA, US
Walter Yu - South San Francisco CA, US

International Classification:

A61K 31/433
A61P 25/28
A61K 9/20
A61K 9/48
A61K 9/10
A61K 9/00
A61K 31/166
A61K 31/415
A61K 31/343
A61K 31/138
A61K 31/135
A61K 31/554
A61K 31/4545
A61K 31/451
A61K 31/5415
A61K 31/19
A61K 31/55
A61K 31/53

Abstract:

Methods of treating neurological diseases and disorders associated with protein aggregation using calpain inhibitors are provided. Said neurological diseases associated with protein aggregation include polyglutamine expansion diseases such as Huntington's disease, Machado-Joseph disease, and spinocerebellar ataxias.